Myelodysplastic syndromes trials in United Kingdom

In United Kingdom 22 Also abroad 369

22 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Where
Aberdeen, Birmingham, Cambridge, High Heaton, Leeds, Leicester, Lincoln, London, Manchester, Nottingham, Oxford, Rhyl, Sunderland
Age
18 years and over
People
225 worldwide
Run by
Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00
Phase 3Taking people
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Where
Birmingham, Boston, Leicester, London, Manchester, Oxford
Age
18 years and over
People
300 worldwide
Run by
Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Leicester, London, Plymouth
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
Where
Manchester
Age
18 years and over
People
54 worldwide
Run by
Amphista Therapeutics Ltd
See details and how to joinNCT07723703
Phase 1Taking people
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Where
Cardiff, Glasgow, London
Age
18 years and over
People
100 worldwide
Run by
Apollo Therapeutics Ltd
See details and how to joinNCT06372717
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Edinburgh, London, Manchester, Newcastle
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 2Taking people
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
Where
Birmingham, Glasgow, London, Maidstone, Manchester, Truro
Age
18 years and over
People
90 worldwide
Run by
Faron Pharmaceuticals Ltd
See details and how to joinNCT07672769 · EU 2026-526706-33-00
Phase 2Taking people
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Where
Leeds, London, Oxford
Age
18 years and over
People
156 worldwide
Run by
Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00
Phase 3Taking people
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Where
Aberdeen, Birmingham, Boston, Cardiff, Coventry, Dorchester, Exeter, Leeds, London, Manchester
Age
18 years and over
People
490 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
London, Maidstone, Manchester, Oxford, Southampton
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Leeds, London
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Edinburgh, Greater Manchester
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 3Taking people
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Where
Edinburgh, Leeds, London, Oxford, Torquay
Age
18 years and over
People
48 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 1/2Taking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Southampton, Stoke-on-Trent, Sutton
Age
18 years and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
Phase 1/2Taking people
Study to Evaluate the Safety and Tolerability of EP0042
Where
London, Manchester
Age
18 years and over
People
70 worldwide
Run by
Ellipses Pharma
See details and how to joinNCT04581512 · EU 2024-514588-24-00
Phase 2Taking people
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Where
Boston, London, Manchester
Age
18 years and over
People
80 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06847867 · EU 2024-519928-24-00
Phase 2Taking people
Methods of T Cell Depletion Trial (MoTD)
Where
Birmingham, Bristol, Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Plymouth, Sheffield, Sutton
Age
16 years to 70 years
People
400
Run by
University of Birmingham
See details and how to joinNCT04888741
No phaseTaking people
WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment
Where
Oxford
Age
18 years and over
People
80
Run by
University of Oxford
See details and how to joinNCT07511829
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 1/2Not yet taking people in United Kingdom
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Where
London, Manchester
Age
16 years to 55 years
People
50
Run by
University of Manchester
See details and how to joinNCT07372885
Phase 2Taking people
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Where
Birmingham, Leeds, London, Manchester
Age
18 years and over
People
50
Run by
Imperial College London
See details and how to joinNCT06355583